CompletedPhase 2NCT02485938

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Capricor Inc.
Principal Investigator
Mark Awadalla
Capricor Inc.
Intervention
Allogeneic Cardiosphere-Derived Cells (CAP-1002)(drug)
Enrollment
25 enrolled
Eligibility
12 years · MALE
Timeline
20162017

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02485938 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials